Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5242-5246

  Davies, Angela M ^a   Chansky, Kari ^a   Lau, Derick H M ^a   Leigh, Bryan R ^a   Gaspar, Laurie E ^a   Weiss, Geoffrey R ^a   Wozniak, Antoinette J ^a   Crowley, John J ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASPIRATION PNEUMONIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DEHYDRATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG USE; ESOPHAGITIS; ESOPHAGUS FISTULA; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG FIBROSIS; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RESPIRATORY TRACT INFECTION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; FEASIBILITY STUDY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247344861     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.0268     Document Type: Article

References (7)

1. Valdivieso M, Kraut MJ, Lattin P, et al: Prospective assessment of clinical trials and combined modality therapy in patients with stage III lung cancer. Proc Am Soc Clin Oncol 12:351, 1993
2. Lau DH, Crowley JJ, Gandara DR, et al: Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16:3078-3081, 1998
3. Gandara DR, Chansky K, Albain K, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer Phase II Southwest Oncology Group Study S9504 J Clin Oncol 21:2004-2010, 2003
4. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993
5. Hainsworth JD, Burris HA III, Erland JB, et al: Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 85:1269-1276, 1999
6. Hainsworth JD, Greco FA: Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy. Semin Oncol 22:45-49, 1995
7. Gatzemeier U, von Pawel J, Gottfried M, et al: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancel J Clin Oncol 18:3390-3399, 2000